Results 111 to 120 of about 14,484 (178)

Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis. [PDF]

PLoS One
Chen Q, Chen T, Lin W, Chen X.
europepmc   +1 more source

Real-World Evidence in Drug Approvals at the European Medicines Agency.

JAMA Netw Open
Bachinger M, Jankowski MA, Kesselheim AS, Krüger N.   +3 more
europepmc   +1 more source

Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty. [PDF]

Pharmacoeconomics
Tran-Duy A, Asbury S, Spelman T, Paterson DL, Buising KL, McDougall C, Solomon M, Crawford R, Adie S, Molnar R, Mulford J, Harris-Brown T, Roney J, de Steiger R, Peel TN, ASAP Trial Group.   +15 more
europepmc   +1 more source

Clinical impact and cost-effectiveness of rapid versus non-rapid antiretroviral therapy initiation in HIV-positive men who have sex with men in China using modelling and 96-week multicenter cohort data. [PDF]

Sci Rep
Zhou K, Wang X, Zhou D, Dai L, Tang W.
europepmc   +1 more source

Commentary on "global disparities in healthcare resources and cancer burden: a population-based systematic analysis of 171 Countries in 2022". [PDF]

Int J Surg
Pezeshkian A.
europepmc   +1 more source

Correction: De Novo Cost‑Effectiveness Model Framework for Nonalcoholic Steatohepatitis-Modeling Approach and Validation. [PDF]

Pharmacoeconomics
Gal P, Feldmajer G, Augusto M, Gani R, Hook E, Bullement A, Philips Z, Smith I.   +7 more
europepmc   +1 more source

Outcome measures in prehabilitation interventions for total hip and knee arthroplasty: A scoping review. [PDF]

Clin Rehabil
Burgess N, Voelker SN, Phillips B, Graco M, Berney S, Denehy L, Edbrooke L.   +6 more
europepmc   +1 more source

Lifetime Effects of Adherence to Cardiovascular and Diabetes Medications in Spain: A Modelling Study in a Population Cohort of 152,117 Patients. [PDF]

Pharmacoeconomics
Sánchez-Viñas A, Wu R, Aznar-Lou I, Mihaylova B, Rubio-Valera M.   +4 more
europepmc   +1 more source

Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context. [PDF]

Pharmacoecon Open
Ursino MG, Milano A, De Angelis FV, Alessi E, Trotta F.   +4 more
europepmc   +1 more source

Estimating the Value of Combination Vaccines: A Methodological Framework. [PDF]

Pharmacoeconomics
Jit M, Portnoy A, Pecenka C, Hausdorff WP, Gill C.   +4 more
europepmc   +1 more source